Back to dashboard
All PlansAdministrativeMedium impact

Voluntary nationwide recall: Cyclosporine

UPMC Health Plan·Transplant Surgery, Nephrology, Cardiothoracic Surgery +1 more·Pharmacy
Effective date
Oct 6, 2023
We identified it
Aug 7, 2026
Days to comply

Summary

Novartis has issued a voluntary nationwide recall of one lot of Sandimmune Oral solution (cyclosporine oral solution, USP), 100 mg/mL, due to crystal formation in some bottles. This medication is used to prevent organ rejection in transplant patients. The billing team must be aware of this recall to handle any patient inquiries, potential claim adjustments, or alternative medication substitutions that may occur.

Action Required

Action needed
Immediately: Notify clinical staff and providers of the cyclosporine recall. Coordinate with pharmacy to identify affected patients currently prescribed this medication and ensure they receive alternative cyclosporine formulations or approved substitutes. Monitor for claim denials or resubmissions related to medication switches. Update patient records to flag the recalled lot number if available. Billing team should be prepared to reprocess claims if patients transition to alternative medications with different HCPCS codes. No billing code changes are required at this time, but track any formulary adjustments communicated by the plan.